In addition, a low level of AR was correlated with decreased sensitivity to anti-HER2 therapies, as revealed by a preclinical study focusing on the impact of AR signaling on HER2+ER− breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.